Skip to main content
. 2018 Nov 14;2018:9475415. doi: 10.1155/2018/9475415

Table 1.

Characteristics of patients with Parkinson's disease in each 3-year study period.

Characteristics 2004–2006 2007–2009 2010–2012 2013–2015
No. % No. % No. % No. %
Total 384 100 855 100 1023 100 1221 100

Sex
Male 141 37.68 321 37.54 401 39.20 483 39.56
Female 243 62.32 534 62.46 622 60.80 738 60.44

Age (y)
0–59 64 16.67 97 11.35 105 10.26 121 9.91
60–69 159 41.40 232 27.13 249 24.34 276 22.60
70–79 129 33.59 385 45.03 480 46.92 545 44.64
80+ 32 8.33 141 16.49 189 18.48 279 22.85

Income
N/A 0 0 95 11.11 77 7.53 74 6.06
Low 92 23.96 171 20.00 193 18.87 253 20.72
Middle 149 38.80 283 33.10 357 34.90 435 35.63
High 143 37.24 306 35.79 396 38.71 459 37.59

Region of residence
Seoul/Incheon 96 25.00 211 24.68 252 24.63 293 24.00
Gyeonggi/Gangwon 84 21.88 187 21.87 240 23.46 314 25.72
Busan/Daegu/Ulsan/Gyeongsang 91 23.70 215 25.15 262 25.61 328 26.86
Daejeon/Sejong/Chungcheong 45 11.72 96 11.23 116 11.34 105 8.60
Gwangju/Jeolla/Jeju 68 17.71 146 17.08 153 14.96 181 14.82

Comorbidities
No 314 81.77 694 81.17 857 83.77 1090 89.27
Yes 70 18.23 161 18.83 166 16.23 131 10.73

Disability grade
None 280 72.92 529 61.87 620 60.61 813 66.58
Mild to moderate (3–6) 59 15.36 189 22.11 249 24.34 323 26.45
Severe (1-2) 45 11.72 137 16.02 154 15.05 85 6.96

Types of antiparkinsonian medications
1-2 219 57.03 531 62.11 632 61.78 764 62.57
3-4 98 25.52 216 25.26 274 26.78 285 23.34
≥5 67 17.45 108 12.63 117 11.44 172 14.09

Levodopa-equivalent dose
<200 69 17.97 165 19.30 195 19.06 234 19.16
≥200, <400 126 32.81 345 40.35 389 38.03 467 38.25
≥400, <600 89 23.18 164 19.18 207 20.23 256 20.97
≥600, <800 46 11.98 70 8.19 105 10.26 118 9.66
≥800 54 14.06 111 12.98 127 12.41 146 11.96

Number of visits
Neurologists 6003 12546 16895 21652
Physiatrists 221 824 2013 3550